Skip to content

Study · Animal study (in vivo) · mouse · 2004

3 results

The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice.

Meirow D, Assad G, Dor J, Rabinovici J

Human reproduction (Oxford, England)29 Apr 2004Cited by 99 (Europe PMC)

PMID15117898 (opens in a new tab)DOI10.1093/humrep/deh257 (opens in a new tab)PepBankPUB-15117898
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice receiving 50 mg/kg cyclophosphamide, cetrorelix reduced primordial follicle destruction to 14% versus 53% without cetrorelix, P < 0.001.

    In plain wordsIn mice receiving 50 mg/kg cyclophosphamide, cetrorelix reduced follicle destruction to 14% versus 53% without cetrorelix.

    Peptide
    Cetrorelix
    Outcome
    DecreasePrimordial follicle destruction with 50 mg/kg cyclophosphamide
    Study

    mousen: not reported in source

    Young female Balb/c mice exposed to cyclophosphamide
    Comparator
    50 mg/kg cyclophosphamide alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · injection · Daily starting 9 days before and 7 days after cyclophosphamide administrationAs given in this study (mouse).

    Measurements

    Primordial follicles destroyed
    14%
    cetrorelix with 50 mg/kg Cy
    Primordial follicles destroyed
    53%
    50 mg/kg Cy alone
    P
    < 0.001
    50 mg/kg Cy comparison

    Source sentences

    Summary
    In each of the Cy groups used, pretreatment with cetrorelix resulted in significantly higher numbers of PMF: in the 50 mg/kg Cy group only 14% were destroyed (cetrorelix group) versus 53% (P < 0.001)
    2 context sentences
    Summary · context
    Highly inbred young Balb/c mice (114 females) were injected with 0, 50 and 75 mg/kg of Cy.
    Summary · context
    In each treatment group, half of the females were injected daily with cetrorelix starting 9 days before and 7 days post-administration of Cy.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice receiving 75 mg/kg cyclophosphamide, cetrorelix reduced primordial follicle destruction to 35% versus 54% without cetrorelix, P < 0.004.

    In plain wordsIn mice receiving 75 mg/kg cyclophosphamide, cetrorelix reduced follicle destruction to 35% versus 54% without cetrorelix.

    Peptide
    Cetrorelix
    Outcome
    DecreasePrimordial follicle destruction with 75 mg/kg cyclophosphamide
    Study

    mousen: not reported in source

    Young female Balb/c mice exposed to cyclophosphamide
    Comparator
    75 mg/kg cyclophosphamide alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · injection · Daily starting 9 days before and 7 days after cyclophosphamide administrationAs given in this study (mouse).

    Measurements

    Primordial follicles destroyed
    35%
    cetrorelix with 75 mg/kg Cy
    Primordial follicles destroyed
    54%
    75 mg/kg Cy alone
    P
    < 0.004
    75 mg/kg Cy comparison

    Source sentences

    Summary
    while in the 75 mg/kg Cy group only 35% of PMF were destroyed versus 54% in animals treated only with Cy (P < 0.004).
    2 context sentences
    Summary · context
    Highly inbred young Balb/c mice (114 females) were injected with 0, 50 and 75 mg/kg of Cy.
    Summary · context
    In each treatment group, half of the females were injected daily with cetrorelix starting 9 days before and 7 days post-administration of Cy.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, the interaction between cetrorelix effect and cyclophosphamide dose was not statistically significant, P = 0.089.

    In plain wordsIn mice, cetrorelix's effect did not vary significantly with cyclophosphamide dose.

    Peptide
    Cetrorelix
    Outcome
    No significant changeInteraction with cyclophosphamide dose
    Study

    mousen: not reported in source

    Young female Balb/c mice exposed to cyclophosphamide
    Comparator
    Different cyclophosphamide doses
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · injection · Daily starting 9 days before and 7 days after cyclophosphamide administrationAs given in this study (mouse).

    Measurements

    Interaction P
    0.089
    two-way ANOVA

    Source sentences

    Summary
    The interaction between the effect of cetrorelix and the different doses of Cy did not reach statistical significance (P = 0.089, two-way ANOVA).
    2 context sentences
    Summary · context
    Highly inbred young Balb/c mice (114 females) were injected with 0, 50 and 75 mg/kg of Cy.
    Summary · context
    In each treatment group, half of the females were injected daily with cetrorelix starting 9 days before and 7 days post-administration of Cy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02518191

Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity

Xiangyun Zongn = 3451 Sept 2015 to 12 Jan 2021

Breast Cancer

Trial pageClinicalTrials.govUpdated 11 Jun 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.